Literature DB >> 14501436

Chronic idiopathic urticaria.

Malcolm W Greaves1.   

Abstract

PURPOSE OF REVIEW: Chronic idiopathic urticaria has long been a demoralizing disease, baffling allergists and dermatologists alike, to the detriment of the patient. Recent findings, however, have shed light on causation in many, though not all, of these patients. The purpose of this review is to bring the reader up to date on the current position regarding aetiology and pathogenesis and the strength of the evidence. The review also seeks to point up rational approaches to diagnosis and treatment in the light of these developments. RECENT
FINDINGS: Chronic idiopathic urticaria encompasses at least two subgroups. One of these is the now well-established entity of autoimmune chronic urticaria, due to autoantibodies against either the high-affinity IgE receptor Fc epsilon R1 or, less commonly, IgE. These patients, who co-segregate with chronic idiopathic urticaria patients having an increased frequency of antithyroid autoantibodies, represent 30-50% of the patients previously designated as having chronic idiopathic urticaria. Convenient routine diagnostic tests for this subset remain elusive. The remaining 50% of patients with chronic idiopathic urticaria remain truly 'idiopathic', although the condition in some may have an autoimmune basis, autoantibodies having eluded current techniques for detection. Selected patients with autoimmune urticaria may benefit from immunotherapy.
SUMMARY: It is now known that in 30-50% of patients with chronic idiopathic urticaria, the condition has an autoimmune basis, although confirmation of the diagnosis in these patients is not straightforward. In selected patients, attempts to establish this diagnosis are worthwhile since there are important therapeutic implications.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14501436     DOI: 10.1097/00130832-200310000-00008

Source DB:  PubMed          Journal:  Curr Opin Allergy Clin Immunol        ISSN: 1473-6322


  30 in total

1.  Celiac disease and chronic urticaria resolution: a case report.

Authors:  M Candelli; E C Nista; M Gabrielli; L Santarelli; G Pignataro; G Cammarota; Giovanni Gasbarrini; Antonio Gasbarrini
Journal:  Dig Dis Sci       Date:  2004-09       Impact factor: 3.199

2.  Idiopathic chronic urticaria and celiac disease.

Authors:  Maurizio Gabrielli; Marcello Candelli; Filippo Cremonini; Veronica Ojetti; Luca Santarelli; Enrico C Nista; Eleonora Nucera; Domenico Schiavino; Giampiero Patriarca; Giovanni Gasbarrini; Paolo Pola; Antonio Gasbarrini
Journal:  Dig Dis Sci       Date:  2005-09       Impact factor: 3.199

Review 3.  The safety and efficacy of desloratadine for the management of allergic disease.

Authors:  William E Berger
Journal:  Drug Saf       Date:  2005       Impact factor: 5.606

4.  Cetirizine: a review of its use in allergic disorders.

Authors:  Monique P Curran; Lesley J Scott; Caroline M Perry
Journal:  Drugs       Date:  2004       Impact factor: 9.546

5.  Contact urticaria: present scenario.

Authors:  Ruchi Bhatia; Ali Alikhan; Howard I Maibach
Journal:  Indian J Dermatol       Date:  2009-07       Impact factor: 1.494

6.  Omalizumab therapy in three patients with chronic autoimmune urticaria.

Authors:  Mona Al-Ahmad
Journal:  Ann Saudi Med       Date:  2010 Nov-Dec       Impact factor: 1.526

Review 7.  Chronic urticaria: recent advances.

Authors:  Malcolm W Greaves; Kian Teo Tan
Journal:  Clin Rev Allergy Immunol       Date:  2007-09-18       Impact factor: 8.667

8.  Rupatadine: pharmacological profile and its use in the treatment of allergic rhinitis.

Authors:  M Sudhakara Rao; D Dwarakanatha Reddy; P S N Murthy
Journal:  Indian J Otolaryngol Head Neck Surg       Date:  2010-01-09

Review 9.  Safety and efficacy of desloratadine in subjects with seasonal allergic rhinitis or chronic urticaria: results of four postmarketing surveillance studies.

Authors:  Claus Bachert; Marcus Maurer
Journal:  Clin Drug Investig       Date:  2010       Impact factor: 2.859

10.  Chronic autoimmune urticaria: where we stand?

Authors:  C L Goh; K T Tan
Journal:  Indian J Dermatol       Date:  2009-07       Impact factor: 1.494

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.